Search results
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market - ET...
The Economic Times· 14 hours agoLondon: Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting ...
Ozempic linked with lower dementia risk, nicotine use, British study finds - ET HealthWorld | Pharma
The Economic Times· 23 hours agoLondon: Novo Nordisk's popular diabetes treatment Ozempic could be tied to a lower risk of cognitive...
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says - ET...
The Economic Times· 1 day agoWeight-loss drugs, including Wegovy and Eli Lilly's Zepbound and Mounjaro, belong to a class known as GLP-1 receptor agonists that slow the process of emptying food contents from the stomach, making users feel full for longer
Vivani to start in-human trial for GLP-1 implant for treating obesity
Medical Device Network· 2 days agoGlobalData estimates that GLP-1 receptor agonist sales for T2D and obesity markets will reach more...
Novo Nordisk applies for more reimbursements for Wegovy in Norway - ET HealthWorld | Pharma
The Economic Times· 2 days agoCopenhagen: Danish drugmaker Novo Nordisk said on Thursday it had applied to the Norwegian health...
Aspect wins $72.75m from Canadian government for bioprinted pipeline
Medical Device Network· 2 days agoAspect’s tissue therapeutic platform is said to combine the company’s bioprinting technology,...
After AdCom rejection, FDA rebuffs Novo Nordisk’s once-weekly insulin
Pharmaceutical Technology· 2 days agoThe US Food and Drug Administration (FDA) has rejected the biologics licence application (BLA) for ...
Pfizer along witth Eli Lilly and Novo Nordisk, enroute to develop their second generation weight...
CNBC TV18· 2 days agoPfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into...
Pfizer moves forward with once-daily weight loss pill
Clinical Trials Arena· 2 days agoThe weight loss market in pharma is in the midst of a boom. Novo Nordisk currently dominates the...
Impact of AI on metabolic disorder clinical trials
Clinical Trials Arena· 2 days agoThe use of AI in metabolic disorders research began increasing in 2023. Obesity and T2D research have been the focus of research since the development of...